This article is more than 5 years old. Information may no longer be current.
Olopatadine 0.77% may reduce ocular itching faster, longer to treat allergic conjunctivitis
Click Here to Manage Email Alerts
Once-daily olopatadine hydrochloride ophthalmic solution 0.77% may perform better than olopatadine 0.1% or 0.2%, with the added benefits of a fast-acting response and reduced itching up to 24 hours after dosing to treat allergic conjunctivitis, according to a study.
Using the conjunctival allergen challenge (CAC) model, the double-masked phase 3 clinical trial randomized 345 patients 2:2:2:1 to receive olopatadine 0.77%, olopatadine 0.2%, olopatadine 0.1% or vehicle, respectively.
Patients’ ocular itching was assessed at 3, 5 and 7 minutes after the onset of action and at 24 hours.
Olopatadine 0.77% was superior in relieving ocular itching at all post-CAC time points and at 24 hours compared with the vehicle (P < .0001).
It was also superior in alleviating itching compared with olopatadine 0.2% at 3 and 5 minutes after CAC and compared with olopatadine 0.1% at 3, 5 and 7 minutes. Olopatadine 0.77% was superior to both groups at 24 hours as well.
Olopatadine 0.77% significantly improved conjunctival and total redness compared with olopatadine 0.2%, olopatadine 0.1% and the vehicle at 3, 5 and 7 minutes. Values were lower but not significant for olopatadine 0.77% at 24 hours regarding conjunctival and total redness.
No safety concerns were noted.
“This suggests advantages of a longer duration of symptom control with olopatadine 0.77% and may translate to improved long-term management of [allergic conjunctivitis], subject satisfaction and, consequently, adherence to therapy,” the study authors said. – by Kristie L. Kahl
Disclosure: McLaurin reports he has received research grants from Aciex, Acucela, Alcon Research Ltd., Allergan, AstraZeneca, Bausch + Lomb, Inotek Pharmaceuticals, InSite Vision, Lexicon Pharma, Mimetogen and Ocular Therapeutix. Please see the full study for a list of all other authors’ relevant financial disclosures.
Collapse
McLaurin E, et al. Cornea. 2015;doi:10.1097/ICO.0000000000000562.
Click Here to Manage Email Alerts